Windtree reports FY2022 net loss $39.2M; cash runway into Q2 2023 only

WINDTREE THERAPEUTICS INC /DE/

Q4 2022 net loss $9.7M ($13.01/share); FY2022 net loss $39.2M ($62.23/share).
Operating loss Q4 $10.8M includes $6.8M rostafuroxin impairment; FY operating loss $41.3M includes $12.6M goodwill impairment.
Cash and equivalents $6.2M at Dec 31, 2022; expects to fund operations into Q2 2023 only.
Raised $1.0M from warrant exercises; R&D expense fell to $1.2M in Q4 from $4.5M YoY.
Istaroxime SEISMiC study met primary endpoint (p=0.017) in early cardiogenic shock; new patent for longer infusion.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WINDTREE THERAPEUTICS INC /DE/ reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Period: the fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On April 3, 2023, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-23-009015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.